Controlled studies in pregnant women show no evidence of fetal risk.Valsartan: Blocks binding of angiotensin II to type 1 angiotensin II receptors; blocks vasoconstrictor and aldosterone-secreting effects of angiotensin IIHydrochlorothiazide: Thiazide diuretic that inhibits sodium reabsorption in distal renal tubules; results in increased excretion of sodium ions and water, as well as potassium and hydrogen ionsAdding plans allows you to compare formulary status to other drugs in the same class.To view formulary information first create a list of plans. Consult your Are you considering switching to AMLODIPINE-VALSARTAN-HCTZ?Are you planning to see a doctor about switching your medication?How long have you been taking AMLODIPINE-VALSARTAN-HCTZ?Are you planning to see a doctor about switching your medication?Selected from data included with permission and copyrighted by First Databank, Inc.
2001
It may take up to 2 weeks before you get the full benefit of this product. WebMD does not provide medical advice, diagnosis or treatment. Valsartan dosage The usual dose of valsartan for adults with high blood pressure is 80 to 160 mg once daily. Valsartan Plus Hydrochlorothiazide: There was no evidence of teratogenicity in mice, rats, or rabbits treated orally with valsartan at doses of up to 600, 100, and 10 mg/kg/day (9, 3.5 and 0.5 times the MRHD), respectively, in combination with hydrochlorothiazide at doses up to 188, 31, and 3 mg/kg/day (38, 13 and 2 times the MRHD). Do not double the dose to catch up.Store at room temperature away from light and moisture. The following information includes only the average doses of this medicine.
It may also increase your risk for Older adults may be more sensitive to the side effects of this drug, especially Some products that may interact with this drug include: Some products have ingredients that could raise your This product may interfere with certain laboratory tests, possibly causing false test results.
Hypertension.
2002
Keep taking this product even if you feel well. Hydrochlorothiazide is present in human breast milkBecause of potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment with this drug combinationA: Generally acceptable. 2001
Applies to the following strengths: 12.5 mg-80 mg; 12.5 mg-160 mg; 25 mg-160 mg; 12.5 mg-320 mg; 25 mg-320 mgInitial dose: 1 tablet (12.5 mg-160 mg) orally once a dayCrCl less than 30 mL/min: Hydrochlorothiazide-valsartan is not recommended because hydrochlorothiazide is not expected to be filtered into the renal tubule (its site of action) when the glomerular filtration rate is less than 30 mL/min.Because valsartan is primarily eliminated by the liver, caution is recommended when advancing doses or giving maximum doses to a patient with liver disease.
1 tablet/day PO (80-160 mg valsartan/12.5-25 mg hydrochlorothiazide); may be titrated after 1-2 weeks of therapy; not to exceed 320 mg valsartan/25 mg hydrochlorothiazide dailyDigestive: Elevated liver enzymes, hepatitis (rare)Discontinue as soon as possible when pregnancy is detected; drug affects renin-angiotensin system, causing oligohydramnios, which may result in fetal injury or deathHypersensitivity to valsartan, hydrochlorothiazide, or sulfonamidesDo not coadminister with aliskiren in patients with diabetesOrthostatic hypotension risk: Initiate combination therapy with 2 antihypertensive drugs cautiously in patients with diabetes or autonomic dysfunction and in geriatric patientsAcute transient myopia and acute angle-closure glaucoma have been reported, particularly with a history of sulfonamide or penicillin allergy (hydrochlorothiazide is a sulfonamide)Use with caution in renal artery stenosis; avoid in bilateral renal artery stenosisCrCl <30 mL/min: Use loop diuretic instead of hydrochlorothiazideHyperkalemia, particularly when coadministered with potassium-sparing diuretics, potassium supplements, or salt substitutes; concurrent therapy with hydrochlorothiazide may reduce the frequency of this effectDual blockade of the renin-angiotensin system with ARBs, angiotensin-converting enzyme (ACE) inhibitors, or aliskiren is associated with increased risk of hypotension, hyperkalemia, and altered renal function (including acute renal failure) in comparison with monotherapyHydrochlorothiazide can cause hypokalemia and hyponatremia; hypomagnesemia can result in hypokalemia that appears difficult to treat despite potassium repletionDrugs that inhibit the renin-angiotensin system can cause hyperkalemia; monitor serum electrolytes periodicallyIn certain patients receiving thiazide therapy, hyperuricemia may occur, or frank gout may be precipitatedHydrochlorothiazide may alter glucose tolerance and raise serum levels of cholesterol and triglyceridesPhototoxicity may occur; instruct patients to protect skin from sun and undergo regular skin cancer screeningAngiotensin system during second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death; most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents; published reports include cases of anhydramnios and oligohydramnios in pregnant women treated with valsartan; when pregnancy is detected discontinue therapy as soon as possibleHypertension in pregnancy increases maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (eg, need for cesarean section, and post-partum hemorrhage); hypertension increases fetal risk for intrauterine growth restriction and intrauterine death; pregnant women with hypertension should be carefully monitored and managed accordinglyOligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and deathThere is limited information regarding presence of drug in human milk, effects on breastfed infant, or on milk production; valsartan is present in rat milk; hydrochlorothiazide is present in human breast milkValsartan is present in rat milk.